Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mangalam Organics Limited (MANORG.NS)
Mumbai, CG, IN
Mangalam Organics Limited, together with its subsidiaries, manufactures and sells chemicals for the industrial and consumer markets in India and internationally. The company offers terpene products, including camphor, camphene, dipentene, isobornyl acetate, isoborneol, isoborneol flakes, sodium acetate trihydrate, terpineol, camphor oil, and pine tar; and resin products, such as terpene and alkyl phenolic resins, penta and glycerol modified ester gums, and rosin esters. It also provides camphor tablets and Bhimseni camphor under the Mangalam brand; and camphor-based home care products, such as camphor cones and sticks, camphor air purifiers and hand wash, camphor soap bars and hand sanitizers, camphor liquid vaporisers and surface cleaners, and camphor mosquito repellants and instacones under the CamPure brand. The company exports its products. It serves various applications, which include religious use, healthcare and hygiene products, fragrance and flavor, paints, cleaning and degreasing agents, textile and dyes, leather tanning, adhesives, tyres, rubbers, chewing gums, and printing ink. The company was formerly known as Dujodwala Products Limited and changed its name to Mangalam Organics Limited in October 2013. Mangalam Organics Limited was incorporated in 1981 and is headquartered in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.00% | -4.38% | +2.15% | +32.90% | +14.57% | +11.68% | -5.81% | +29.18% | -39.55% | -39.55% | -39.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Chemicals - Specialty: +4.7%+17.5% ★ Q1'26: +2.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+101.5% ★ Q1'26: +9.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-9.9% Q1'26: -50.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+9.7% ★ Q1'26: +23.5% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+6.9% ★ Q1'26: +14.3% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+1.6% Q1'26: +6.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×4.09× Q1'26: 1.92× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sanjay Bhardwaj | Chief Executive officer | 3M | male |
| Shrirang V. Rajule | Chief Financial Officer | 912.0K | male |
| Kamal Kumar Ramgopal Dujodwala | Whole-time Executive Chairman | — | male |
| Akshay Kamalkumar Dujodwala | Chief Strategy Officer | — | male |
| Pannkaj R. Dujodwala | MD & Whole Time Director | — | male |
| Mahesh Lahurao Navathar | Additional Executive Director | — | male |
| Charmi Shah | Company Secretary, Compliance Officer & Nodal Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MANORG.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
